Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Protein Kinase Inhibitors in Oncology Drug Pipeline Update' returned 28 results - Page 1 of 2  FEATURED RESULTS Drug Delivery in Cancer - Technologies, Markets and Companies Cancer Diagnostic Testing World Markets Antibody Drug Target Atlas in Oncology Immunotherapy in Oncology: Gaining Momentum Innovations in Oncology Diagnostics: Technological Advances,...   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2011   Bioseeker, Feb 2011 and the accumulated number of ceased drugs over the last years amount to another 228 (227) drugs. Protein Kinase Inhibitors In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one Oncology Pipeline Database   La Merie, Feb 2012 Menu: - Antibody-Drug Conjugates (ADC) - Aurora Kinase Inhibitors - Bcr-Abl and Src Kinase Inhibitors - c-MET/HGF Inhibitors - CD3 Antagonists - CD19 Antagonists - CD20 Antibodies - CD22 Analytical Tool - Protein Kinase Inhibitors in Oncology   Bioseeker, Feb 2011 - Where to Commercialize? Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2011- The Package Includes - A progress analysis on current and emerging drugs - Information on most companies active Competitor Analysis: Bcr-Abl and Src Kinase Inhibitors   La Merie, July 2009, Pages: 20 in research and development of Bcr-Abl and Src kinase inhibitors in oncology and other indications. In addition, the report lists company-specific R&D pipelines of Bcr-Abl and Src kinase inhibitors. Competitor projects Immunotherapy in Oncology Drug Pipeline Update 2011   Bioseeker, Feb 2011 In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 336 (315) different targets. These targets are further categorized Nucleic Acid Therapies in Oncology Drug Pipeline Update 2011   Bioseeker, Feb 2011 the last years amount to another 165 drugs. Nucleic Acid Therapies In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 173 Biologicals in Oncology Drug Pipeline Update 2011   Bioseeker, Feb 2011 This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 675 companies plus partners developing Radiation Therapy in Oncology Drug Pipeline Update 2011   Bioseeker, Feb 2011 . Radiation Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 172 (145) different targets. These targets are further Peptides in Oncology Drug Pipeline Update 2011   Bioseeker, Feb 2011 number of ceased drugs over the last years amount to another 108 (108) drugs. Peptides In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified Angiogenesis in Oncology Drug Pipeline Update 2011   Bioseeker, Feb 2011 and the accumulated number of ceased drugs over the last years amount to another 136 (128) drugs. Angiogenesis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them Proteins in Oncology Drug Pipeline Update 2011   Bioseeker, Feb 2011 projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 152 drugs. Proteins In Oncology Drug Pipeline Update lists all Competitor Analysis: CHK and KSP/Eg5 Inhibitors   La Merie, Aug 2009, Pages: 19 The present Competitive Intelligence Report about checkpoint kinase (CHK) and kinesin spindle protein (KSP) or Eg5 inhibitors provides a competitor evaluation in the field of novel molecular Competitor Analysis - PI3K-AKT-mTOR Inhibitors   La Merie, June 2011, Pages: 100 includes a compilation of current active projects in research and development of PI3K-AKT-mTOR inhibitors in oncology and other indications. In addition, the report lists company-specific R&D pipelines of PI Antibodies in Oncology Drug Pipeline Update 2011   Bioseeker, Feb 2011 . In addition, there are 6 (2) suspended drugs and the accumulated number of ceased drugs over the last years amount to another 291 (285) drugs. Antibodies In Oncology Drug Pipeline Update lists all drugs Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas   Bioseeker, Sep 2007, Pages: 500 care indications - Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase inhibitor- and Vaccine drugs for the treatment of cancer - The included competitive landscape between the five big Therapeutic Peptides in Oncology: Drug Pipeline Update 2009   Bioseeker, Jan 2009 the Therapeutic Peptides in Oncology: Drug Pipeline Update is organized. How May Drug Pipeline Update Be of Use? - Show investors/board/management that you are right on top of drug development progress in your Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth   Datamonitor, April 2010, Pages: 243 with greater efficacy Small molecules Small molecules targeting tyrosine kinases have been a significant development in oncology drug discovery Classification of pipeline products Angiogenesis inhibitor ID Signaling Pathway in Oncology Drug Pipeline Update 2011   Bioseeker, Feb 2011 . In addition, the accumulated number of ceased drugs over the last years amount to another 7 drugs. Id Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each Competitor Analysis: VEGF and VEGF-R Agonists and Antagonists   La Merie, Sep 2009, Pages: 133 - VEGF and VEGF-R Antagonists in Oncology -- Avastin Pipeline -- Biologics as VEGF and VEGF-R Antagonists -- Small Molecules as VEGF RTK Inhibitors -- Sutent Pipeline -- Nexavar Pipeline -- Selective Antibody Drug Targets and Special Focus on Leukemias & Lymphomas   Bioseeker, Dec 2007, Pages: 430 -Specific Selection Pressures Table 71: Antibodies in Oncology Reported to Act as Protein Kinase Inhibitors Table 72: Cancer Indicaions by Number of Known Antibody Targets, Number of Antibody Drugs Results:  First -   Prev -   1 -   2 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network